Undisclosed CDKN2A modulator / Ideaya Biosci - LARVOL DELTA

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update (PRNewswire) - "IDE892 is being evaluated as a monotherapy agent in MTAP-deleted solid tumors, including NSCLC and PDAC, and targeting combination FPI with IDE397 (MAT2A) in mid-2026; Targeting nomination of a first-in-class CDKN2A development candidate in H2 2026 and IND in H1 2027; prevalence of CDKN2A-deficiency has been reported at over 80% in PDAC; IDEAYA will deprioritize combination activities with Trodelvy as part of a strategic prioritization of its proprietary MTAP-deleted and CDKN2A pipeline."

IND • Pipeline update • Trial status • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (PRNewswire) - "Nomination of a development candidate for a potential first-in-class program targeting CDKN2A, the most common co-alteration of MTAP, expected in H2 '26 followed by IND submission to the U.S. FDA in H1 '27....IDE574 (KAT6/7)...targeting to initiate a Phase 1 dose escalation trial in patients with breast, lung, prostate and colorectal cancers Q1 '26."

IND • New P1 trial • Pipeline update • Breast Cancer • Colorectal Cancer • Lung Cancer • Prostate Cancer